glp-1 dpp 4 combination 𝐋𝐚𝐭𝐞𝐬𝐭 𝐩𝐨𝐬𝐢𝐭𝐢𝐨𝐧 𝐨𝐟 𝐃𝐏𝐏-𝟒 𝐢𝐧𝐡𝐢𝐛𝐢𝐭𝐨𝐫𝐬 (𝐞.𝐠., 𝐬𝐢𝐭𝐚𝐠𝐥𝐢𝐩𝐭𝐢𝐧, 𝐬𝐚𝐱𝐚𝐠𝐥𝐢𝐩𝐭𝐢𝐧, 𝐥𝐢𝐧𝐚𝐠𝐥𝐢𝐩𝐭𝐢𝐧, 𝐚𝐥𝐨𝐠𝐥𝐢𝐩𝐭𝐢𝐧, 𝐯𝐢𝐥𝐝𝐚𝐠𝐥𝐢𝐩𝐭𝐢𝐧) 𝐢𝐧 𝐭𝐡𝐞 𝟐𝟎𝟐𝟓 𝐀𝐃𝐀 𝐒𝐭𝐚𝐧𝐝𝐚𝐫𝐝𝐬 𝐨𝐟 The Role of DPP-4 Inhibitors

That's why, when reported, outcomes tend to be inconsistent and heavily dependent on the person's routine

Additionally, use of proton pump inhibitors (PPIs) and diuretics (or "water pills") such as furosemide and hydrochlorothiazide can lead to magnesium deficiency over time

Consider the timescales

Because several of those triggers leave fingerprints in the blood, a focused panel can point to a cause that is treatable rather than permanent

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have demonstrated clinically significant cardiovascular and kidney benefits in individuals with type 2 diabetes (T2D) and cardiovascular benefits in those with obesity and atherosclerotic cardiovascular disease at baseline 6,7

With the right approach, you can mitigate many of these potential long-term risks